Welcome to our dedicated page for LakeShore Biopharma Co. SEC filings (Ticker: LSB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LakeShore Biopharma Co., Ltd. files Form 6-K reports as a foreign private issuer documenting material events, governance matters, capital-structure disclosures, shareholder voting matters, and operating and financial results. The filings describe the company’s biopharmaceutical business, including vaccines and therapeutic biologics for infectious diseases and cancer, the PIKA® platform, and clinical or regulatory disclosures for its product programs.
The filing record also documents corporate-status and transaction-related disclosures, including Nasdaq delisting and OTC trading status, material agreements, extraordinary general meeting notices, and board or special committee governance. Additional reports address arbitration awards and related liabilities involving company subsidiaries, framed as material events and risk disclosures.
LakeShore Biopharma’s controlling shareholder group filed Amendment No. 5 to its Schedule 13D, outlining a sharply revised going‑private proposal. The consortium now proposes to buy all publicly held ordinary shares at US$0.06 per share, compared with the prior US$0.90 offer, via equity funding and rollover of existing holdings.
The filing cites arbitral awards imposing approximately RMB576.5 million of monetary liabilities and related litigation uncertainty as key reasons for the lower price, warning these could materially weaken the company’s financial condition. If completed, the merger would take LakeShore private, terminate SEC registration and remove its shares from the OTC Pink market. The proposal remains non‑binding, with no assurance that definitive agreements or a transaction will be consummated.
LakeShore Biopharma reports that the buyer group for its previously announced going‑private deal at $0.90 per share has sent a notice claiming a “Company Material Adverse Effect” under the merger agreement.
The claim is based on arbitral awards that created an approximate RMB576,500,000 financial liability. Citing this, the buyer group asserts it has the right not to consummate the merger and says it will not attend or vote at the extraordinary general meeting that was scheduled for February 12, 2026. In response, the company has postponed the meeting indefinitely and will disregard any previously submitted proxy cards, while it reviews the buyer group’s position and its own options.
LakeShore Biopharma’s buyer group has determined that recent arbitration awards mean its planned merger cannot proceed on current terms. Three awards from the Kaifeng Arbitration Commission require certain PRC subsidiaries to pay about RMB576.5 million, which the group believes causes a “Company Material Adverse Effect” under the merger agreement.
Because this condition to closing can no longer be met, the buyer group has notified the company it will not proceed with closing and its members will not attend or vote at the February 12, 2026 extraordinary general meeting. The group, however, plans to discuss potential amended transaction terms with the issuer.
LakeShore Biopharma Co., Ltd has called an extraordinary general meeting of shareholders for February 12, 2026 at 11 a.m. (Beijing time) in Beijing. Shareholders will be asked to consider and vote on authorizing and approving a previously announced Agreement and Plan of Merger with Oceanpine Skyline Inc. and its subsidiary Oceanpine Merger Sub Inc., along with a related Cayman Islands plan of merger.
At the effective time of the merger, Merger Sub will merge into LakeShore Biopharma, which will survive as a wholly owned subsidiary of Oceanpine Skyline Inc. If completed, the merger will result in LakeShore Biopharma becoming a privately held company, and its ordinary shares and warrants will no longer be quoted on any public marketplace, including the OTC Pink tier, and will cease to be registered under the U.S. securities laws.
The board of directors, following a unanimous recommendation from a special committee of independent directors, has approved the merger documents and resolved to recommend that shareholders vote FOR the proposals. Shareholders of record as of 5 p.m. Cayman Islands time on January 16, 2026 are entitled to attend and vote at the meeting. Additional details are provided in the Schedule 13E-3 transaction statement and definitive proxy statement filed with the SEC.
LakeShore Biopharma (LSB) filed a Form 6‑K announcing it has entered into a definitive agreement for a going‑private transaction. The filing furnishes two exhibits: a press release and an Agreement and Plan of Merger dated November 4, 2025.
The merger agreement is among LakeShore Biopharma Co., Ltd, Oceanpine Skyline Inc., and Oceanpine Merger Sub Inc. The 6‑K provides notice of the agreement and includes the full documents as exhibits.
LakeShore Biopharma Co., Ltd filed a Form 6-K as a foreign private issuer, mainly to furnish a press release about its stock trading status. The company announced a transition to trading on the OTC market following a Nasdaq delisting. The report is signed by Director and Chief Financial Officer Rachel Yu on September 22, 2025.